ClinicalTrials.gg
Not yet recruitingNCT07605637Updated May 26, 2026

Early Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of STR-P005

An interventional study of STR-P005 dose group in Relapsed/Refractory Autoimmune Diseases, sponsored by Beijing GoBroad Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Beijing GoBroad Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a single-center, single-arm, open-label, investigator-initiated early exploratory clinical trial designed to evaluate the safety and efficacy of STR-P005 in participants with relapsed/refractory autoimmune diseases.

The study will employ a traditional "3+3" dose-escalation design, with 3 dose groups: XXmg/kg, XXmg/kg, XXmg/kg. Dose Group 1 is the starting dose. This group includes two cohorts, A and B, to optimize the dosing frequency of STR-P005. Cohort A will receive doses Q3D (once every 3 days) on Days 1, 4, 7 (3 doses per cycle), for up to 2 cycles. Cohort B will receive doses Q4D (once every 4 days) on Days 1, 4 (2 doses per cycle), for up to 2 cycles. Based on preliminary safety, efficacy, PK/PD data from Cohorts 1A and 1B, the superior regimen will be selected for escalation to Dose Groups 2 and 3. If no optimal dose is identified after escalating through the 3 dose groups, additional higher doses may be explored after SRC discussion based on all accumulated preliminary safety, efficacy, and PK/PD data to further evaluate the safety and efficacy of STR-P005.

02

Conditions studied

  • Relapsed/Refractory Autoimmune Diseases

Browse trials for

Keywords

  • SLE
  • dcSSc
  • ANCA
  • AAV
  • IIM
  • SS
03

In context

Autoimmune Diseases

804 studies on the registry are indexed under Autoimmune Diseases; 273 are open to participants now.

This study's planned enrollment of 18 is below the median of 40 across 543 interventional studies indexed under Autoimmune Diseases.

Browse Autoimmune Diseases studies →

Lead sponsor

Beijing GoBroad Hospital is the lead sponsor of 35 studies on the registry; 35 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Voluntarily participate and sign . 2. Age 18 to 75 years (inclusive). 3. Confirmation of positive CD19 expression on peripheral blood B cells by flow cytometry.

    4. Adequate organ function:

    1. Hematology: (ANC) ≥1.0×10\^9\^/L, absolute lymphocyte count (ALC) ≥0.1×10\^9\^/L, ≥80 g/L, count (PLT) ≥50×10\^9\^/L. Transfusion and growth factors cannot be used within 7 days prior to screening to meet these requirements.
    2. Coagulation: (INR) ≤1.5 × (ULN), and activated partial thromboplastin time (APTT) ≤1.5 × ULN.
    3. Liver function: Serum , ALT ≤3.0 × ULN, total ≤1.5 × ULN (for participants with Gilbert's syndrome, total bilirubin \<3.0 × ULN).
    4. Renal function: Serum creatinine ≤1.5 × ULN or (CrCl) ≥60 mL/min (Cockcroft Gault formula); if renal involvement, CrCl ≥45 mL/min. \|
    5. Cardiac function: (NYHA) class I or II, (LVEF) ≥50% by echocardiography (ECHO), and no arrhythmia, pericardial effusion, valvular disease, or ischemic heart disease (IHD) within 8 weeks prior to screening.
    6. Oxygen saturation: ≥92% while breathing room air at rest (by pulse oximetry); no clinically significant pleural effusion.

Exclusion criteria

Exclusion Criteria:

  • Participants meeting **ANY** of the following exclusion criteria cannot be enrolled:

    1. Previous treatment with any cellular immunotherapy, unless there is evidence that engineered immune cells have disappeared and B cells are still present in peripheral blood.
    2. Failure to meet the following treatment :

      1. Use of therapeutic doses of (prednisone ≥20 mg/day or equivalent) within 72 hours before first dose, though topical or inhaled steroids are allowed.
      2. Use of mycophenolate mofetil or its derivatives, azathioprine, calcineurin inhibitors (e.g., tacrolimus, cyclosporine), mTOR inhibitors (e.g., sirolimus, everolimus), JAK inhibitors (e.g., tofacitinib, ruxolitinib, upadacitinib) within at least 2 weeks before screening.
      3. Use of cytotoxic drugs such as cyclophosphamide, methotrexate within at least 3 weeks before screening.
      4. Use of belimumab, B-cell targeting antibodies (e.g., anti-CD20) within at least 1 month or more; anti-cytokine antibodies within at least 2 months; natalizumab, anti-CD52, anti-CD38, ATG within at least 3 months before screening.
      5. Other monoclonal, bispecific, trispecific antibodies, ADCs, or any B-cell depleting drugs must be washed out for 3 months or 5 half-lives (whichever is shorter) before screening.
      6. Undergone plasmapheresis, plasma separation, hemodialysis, IVIG within 2 weeks before screening.
    3. History of ≥ Grade 2 bleeding within 30 days before screening; or requiring long-term continuous use of anticoagulants (e.g., warfarin, low molecular weight heparin, Factor Xa inhibitors), unless ≤1.5 × .
    4. Severe renal disease: Severe lupus nephritis within 8 weeks before screening [defined as urine protein >6g/24h or serum creatinine >2.5 mg/dL or 221 μmol/L or (Cockcroft Gault) \<30 mL/min], or active nephritis requiring treatment with prohibited medications, or requiring prednisone >100 mg/day or equivalent corticosteroid therapy for ≥14 days.
    5. Severe pulmonary disease within 3 months before screening, such as moderate-to-severe pulmonary arterial hypertension (mean pulmonary artery pressure >60 mmHg by ECHO), requiring oxygen therapy via mask or non-invasive/invasive mechanical ventilation at screening.
    6. History of lupus crisis within 3 months before screening, such as active CNS lupus, severe hemolytic anemia, severe thrombocytopenic purpura, severe granulocytopenia, severe myocardial injury, severe lupus pneumonitis or pulmonary hemorrhage, severe lupus hepatitis, severe vasculitis, etc.
    7. History or symptoms of active non-lupus-related CNS disease within 6 months before screening (excluding isolated trigeminal nerve disease), including but not limited to: cerebrovascular disease, encephalitis, brain injury, aneurysm, cerebellar disease, organic brain syndrome, Parkinson's disease, etc., as well as symptoms like epilepsy, convulsions, aphasia, dementia.
    8. Occurrence of any of the following cardiovascular diseases within 6 months before screening (including but not limited to):

      1. Congestive heart failure, myocardial infarction, unstable angina, coronary angioplasty, stent implantation, coronary/peripheral artery bypass grafting.
      2. Severe arrhythmias requiring treatment (e.g., sustained ventricular tachycardia, ventricular fibrillation, Torsade de Pointes); congenital long syndrome, left anterior hemiblock (bifascicular block), complete left bundle branch block or high-grade AV block; history of severe non-ischemic cardiomyopathy. Asymptomatic right bundle branch block is allowed.
      3. Uncontrolled hypertension (systolic BP >160 mmHg and/or diastolic BP >100 mmHg), history of hypertensive crisis or hypertensive encephalopathy.
      4. Current evidence of active cardiac involvement, such as pericarditis, pericardial effusion, myocarditis.
    9. Active tuberculosis or latent tuberculosis at screening (defined as positive tuberculin skin test or interferon-gamma release assay, without clinical symptoms or radiological evidence).
    10. Positive for antibodies, or , , CMV-DNA exceeding assay upper limit of normal at screening.
    11. Presence of uncontrolled fungal, bacterial, viral, or other infections deemed unsuitable for study participation by the investigator.
    12. Presence of uncontrolled diabetes ( ≥7.0%); uncontrolled thyroid disease (TSH >10 mIU/L or \<0.1 mIU/L, and FT4 outside normal range).
    13. History of major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell transplant within 12 weeks or autologous stem cell transplant within 6 weeks prior to screening.
    14. Congenital immunoglobulin deficiency.
    15. Thrombotic thrombocytopenic purpura (TTP)/thrombotic microangiopathy (TMA).
    16. History of other diseases (including but not limited to eosinophilic granulomatosis with polyangiitis, cryoglobulinemic vasculitis, inclusion body myositis, anti-GBM disease, Behçet's disease, or Takayasu's arteritis) requiring systemic treatment, besides the target indication.
    17. Family history of non-IIM conditions such as drug-induced myopathy, HIV-associated myopathy.
    18. Previous or concurrent other active , including patients with cancer-associated polymyositis/dermatomyositis. Exceptions: cured cervical carcinoma in situ with no recurrence for at least 2 years, non-invasive basal cell or squamous cell skin cancer, radically treated localized prostate cancer, ductal carcinoma in situ of the breast post-mastectomy, and papillary thyroid cancer.
    19. History of or life-threatening reaction to the study drug or any of its components or formulation ingredients.
    20. Pregnant or breastfeeding women.
    21. Vaccination with any within 6 weeks before first dose, or planned vaccination within 3 months after treatment.
    22. Participation in other interventional clinical studies, received active drug within 3 months before signing ICF, or intention to participate in another clinical trial or receive autoimmune disease treatment outside the protocol during the entire study.
    23. Psychiatric patients with depression or suicidal tendencies.
    24. Other factors deemed by the investigator to make the participant unsuitable for enrollment or unable to complete the study.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Dose1

    Drug: STR-P005 dose group

Interventions

  • DrugSTR-P005 dose group

    STR-P005 infusion

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for May 2027, 11 months later.

Of 78 non-industry interventional studies with no phase under Autoimmune Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 62. This study's planned 11 months is below that.

Counting every sponsor, half of 87 studies reached it within 31 months; a quarter within 15 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 26, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
May 30, 2027
CompletionEst.
Nov 30, 2027
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07605637
Lead sponsor
Beijing GoBroad Hospital
Collaborators
Starna Therapeutics
Responsible party
Sponsor
First posted
May 26, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
May 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
May 26, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion